November 2, 2005 -- Johnson & Johnson received FTC permission to buy Guidant, but J&J continued to express doubts the merger would take place, given the recent problems at Guidant; Tarceva from Genentech and OSI Pharma was approved to treat pancreatic cancer; Roche released interim Phase III data showing Xeloda also provided a survival benefit to pancreatic cancer patients; Emageon bought the Camtronics division of Analogic for $40 million; Dor BioPharma will acquire Gastrotech of Denmark for $9 million in Dor stock; and Merck signed a second cancer partnership with Aveo Pharma. The Centient Biotech 200™ was almost 26 points higher at 3770.04, a rise of .68%. More details...
